Skip to content

Arcus Biosciences RCUS Book value per share

Book value per share at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$291.77+10.4%
AbbVie logo
AbbVieABBV
-$3.75-568%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$10.57-8.8%
Incyte logo
IncyteINCY
$27.19+46.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
$1.29-8.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.85-22.2%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Calculated from Arcus Biosciences’s reported figures.

Based on the most recent quarter.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's book value per share?
Arcus Biosciences (RCUS) reported book value per share of $4.18 in Q1 2026.
How has Arcus Biosciences's book value per share changed year-over-year?
Arcus Biosciences's book value per share decreased by 22.6% year-over-year, from $5.40 to $4.18.
What is the long-term trend for Arcus Biosciences's book value per share?
Over 5 years (2020 to 2025), Arcus Biosciences's book value per share has grown at a -8.5% compound annual growth rate (CAGR), from $9.16 to $5.88.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.